By Sony Sherpa, MBBS, MD
Table of contents
- Understanding bulky disease in lymphoma
- Types of lymphoma associated with bulky disease
- Diagnostic approaches
- Staging and classification
- Treatment strategies
- Living with bulky disease lymphoma
- FAQs
- Blood Cancer United cancer research impact
- Conclusion
- Sources
Bulky disease in lymphoma is defined as a large area of lymphoma that measures above a certain size, usually 10 centimeters or greater. It may be a single large lymph node or a group of nodes that have grown together to form a single mass.
This condition is not a separate type of lymphoma—it is a way to describe how extensive the disease is when it is first diagnosed. Bulky disease has a higher tumor burden. So, it requires adjustments in treatment for a better outcome.
The term is used in Hodgkin and non-Hodgkin lymphoma, though specific size thresholds and criteria vary between subtypes (Cheson et al. 2014).
Understanding bulky disease lymphoma is important. It can change the stage of lymphoma, the treatment plan, outcomes of therapy, and the long-term prognosis. If diagnosed early and treated properly, people with bulky disease can achieve remission and live full lives.
Types of lymphoma associated with bulky disease
Hodgkin lymphoma
In people diagnosed with Hodgkin lymphoma (HL), bulky disease is quite common. It is more frequently seen in younger patients.
For Hodgkin lymphoma, bulky disease is typically defined as a single nodal mass measuring 10 centimeters or greater. It can also refer to a mass larger than one-third of the chest diameter as determined by CT scan (Cheson et al. 2014).
It is initially diagnosed by the appearance of a large tumor mass in the chest, also known as a mediastinal mass. In fact, this is a frequent way of how a bulky Hodgkin lymphoma presents in a clinical setting (Townsend and Linch 2012).
When an initial diagnosis of Hodgkin lymphoma is made, the presence of bulky disease affects the stage of the disease and how to treat it. Although the lymphoma may be limited to one or two areas, a large tumor categorizes the patient in a more advanced and higher stage (Cheson et al. 2014).
Once diagnosed with bulky disease, the treatment plan entails a combination of chemotherapy and radiation therapy. Response to the treatment is then evaluated using PET-CT scans, and the need for additional therapies is assessed (Barrington et al. 2014).
Treatment plans are usually individualized with a target of reducing the tumor bulk while also minimizing both short- and long-term side effects (Cheson et al. 2014).
Non-Hodgkin lymphoma
Bulky disease may also be seen in non-Hodgkin lymphoma (NHL), especially in aggressive subtypes like diffuse large B-cell lymphoma (DLBCL) (Townsend and Linch 2012). DLBCL is one of the most common forms of non-Hodgkin lymphoma and often presents with bulky tumor size at the time of diagnosis.
Defining bulky disease in non-Hodgkin lymphoma is less consistent. Suggested thresholds vary depending on the subtype. Currently, the recommendation is to record the largest tumor dimension by CT (Cheson et al. 2014).
In bulky non-Hodgkin lymphoma, there is a higher risk of relapse and often requires more aggressive treatment. This is because when lymphoma has spread outside the lymph nodes, it can complicate management.
Treatment usually involves chemotherapy with multiple drug regimens and radiation therapy for large masses. Targeted therapies and immunotherapies for treatment resistant bulky disease are currently being studied (Kuruvilla et al. 2011; Wang et al. 2015).
Diagnostic approaches
Imaging techniques
Imaging is key in diagnosing bulky disease lymphoma. PET scans and CT scans are the most important imaging tools used in diagnosing and staging lymphoma. These imaging tools can evaluate the size, location, and extent of the spread of the lymphoma (Barrington et al. 2014).
A CT scan provides detailed images of targeted regions within the body. It is especially beneficial for measuring the size of a large tumor mass.
CT scans can also help identify distant spread and mass effect in lymphoma. In lymphoma, mass effect describes how an enlarged tumor or lymph node presses on nearby organs or tissues, potentially causing symptoms due to this pressure (Cheson et al. 2014).
A PET scan is often used in conjunction with a CT scan to assess tumor activity. PET scans work by detecting areas of increased glucose uptake. This doesn’t mean that eating more sugar causes problems, it simply corresponds to the activity of the tumor.
It is particularly useful in monitoring response to chemotherapy, evaluating residual masses after treatment, and planning radiation therapy (Barrington et al. 2014).
Biopsy and tissue analysis
While imaging can show bulky disease, a biopsy is essential to confirm the diagnosis of lymphoma and identify its specific type. In a biopsy, a sample of tissue is taken from a swollen lymph node or mass and is examined under a microscope to determine which type of lymphoma and the specific subtype.
Further tests can also be done on the biopsy sample to look for specific biomarkers that predict how the lymphoma will respond to treatment or whether it may be treatment-resistant (Swerdlow et al. 2008).
Staging and classification
The Lugano Classification is the current standard for bulky disease staging of Hodgkin and non-Hodgkin lymphoma, using PET-CT scans to assess how far the disease has spread. (Cheson et al. 2014). It includes:
- Stage I: One lymph node region or a single distant site
- Stage II: Two or more regions on the same side of the diaphragm
- Stage III: Regions on both sides of the diaphragm
- Stage IV: Widespread involvement, including organs like liver or bone marrow
Prognostic implications
Bulky disease indicates a higher tumor burden and may have a greater chance of relapse risk, especially in aggressive lymphoma subtypes. However, timely treatment informed by imaging and accurate staging significantly improves the outcome (Cheson et al. 2014; Townsend and Linch 2012).
Treatment strategies
The management of bulky disease in lymphoma depends on several factors, including the type of lymphoma, stage of disease, tumor location, patient age, overall health, and treatment tolerance. These considerations guide hematologist-oncologists in selecting the safest and most effective therapy plan.
Chemotherapy regimens
Standard chemotherapy protocols for bulky disease lymphoma include multi-drug regimens such as (National Cancer Institute 2015):
- ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) for Hodgkin lymphoma
- R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) for non-Hodgkin lymphoma
In bulky disease cases, treatment plans may include additional cycles of chemotherapy or concurrent radiotherapy to manage the large tumor mass effectively.
Radiation therapy
Radiation therapy is sometimes included in the management of bulky lymphomas either after chemotherapy or concurrently to further shrink residual disease. The goal of radiotherapy is to reduce the risk of relapse and minimize long-term side effects. In Hodgkin lymphoma, if PET-CT scans show persistent activity, involved-site radiation therapy (ISRT) may be used for remaining masses (Cheson et al. 2014; Engert 2015).
Targeted therapies
Targeted and immune-based therapies like checkpoint inhibitors, CAR T-cell therapy, and monoclonal antibodies bring new hope for people who do not respond to established treatments for bulky disease in lymphoma.
There are several ongoing clinical trials studying the efficacy of these treatments. For people with treatment-resistant bulky disease, participation in such trials is recommended. Such treatments are aimed at reducing tumor burden while minimizing toxicity (Kuruvilla et al. 2011; Wang et al. 2015).
Latest research
Recent advancements in imaging have made it easier to track response to chemotherapy in real-time. PET-adapted therapy is now being studied to help tailor treatments for each patient by analyzing mid-treatment scan results.
Also, new drugs are being tested for people with bulky lymphoma that do not respond to conventional treatment (Barrington et al. 2014; Engert 2015).
If you live with bulky lymphoma and are interested in exploring clinical trial options, our Clinical Trial Nurse Navigators will speak with you about clinical trials and other treatment options specific to your cancer and unique situation and personally guide you through the entire clinical trial process.
Living with bulky disease lymphoma
Managing bulky lymphoma includes managing the side effects from chemotherapy and radiation. It’s important to go for regular doctor appointments to monitor relapse.
Emotional and mental support is also important at this time. Blood Cancer United provides resources such as support groups, counseling, and information to guide people with lymphoma and their caregivers.
FAQs
Does having bulky disease mean the cancer is more advanced?
Not always, but it usually means there is a higher tumor burden, which can change how doctors choose to treat it (Cheson et al. 2014).
How is bulky disease detected?
It is typically identified through imaging studies such as CT or PET-CT scans that measure the size of the tumor and its metabolic activity (Cheson et al. 2014; Townsend and Linch 2012).
What are the symptoms of bulky disease lymphoma?
Symptoms often relate to the pressure, also known as the mass effect, from large tumors. Some of the symptoms are cough, chest pain, or swelling, but some patients may have few or no symptoms (Cheson et al. 2014; Townsend and Linch 2012).
Is radiation always needed for bulky lymphoma?
Radiation is not always needed. It may be recommended based on residual mass, PET-CT results, and response to other treatment regimens (Cheson et al. 2014; Engert 2015).
Can bulky disease lymphoma be cured?
Yes, many people with bulky disease can be cured, but this requires prompt and appropriate treatment (Cheson et al. 2014; Townsend and Linch 2012).
Are new treatments available for bulky disease?
Yes, there are newer treatments such as targeted and immune-based therapies being studied in clinical trials for people whose lymphoma does not respond to standard treatments (Kuruvilla et al. 2011; Wang et al. 2015).
What support is available for people living with bulky disease lymphoma?
Blood Cancer United offers financial support, educational materials, caregiver resources, emotional support and counseling.
Blood Cancer United cancer research impact
Blood Cancer United is committed to improving outcomes for people with lymphoma—and any other blood cancer. Blood Cancer United funds innovative research into more effective, less toxic treatments, including chemotherapy protocols for bulky mass lymphoma.
The organization also provides financial assistance, educational resources, and patient navigation services. People living with lymphoma can connect with support groups and access comprehensive care plans through Blood Cancer United’s community outreach programs.
If you would like to support ongoing research and help others living with lymphoma, consider donating to Blood Cancer United today. Your support makes a difference.
Conclusion
Bulky disease in lymphoma can significantly impact disease treatment and outcome. This is true for both Hodgkin and non-Hodgkin lymphoma. Identifying and managing bulky masses early can help improve prognosis.
With modern diagnostic tools, newer treatment modalities, and support, people with bulky disease lymphoma can receive the individualized care they need. Blood Cancer United is there to help at every step, ensuring that no one faces lymphoma alone.
Sources
- Cheson, Bruce D., Richard L. Fisher, Sally F. Barrington, et al. “Recommendations for Initial Evaluation, Staging and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification.” Journal of Clinical Oncology 32, no. 27 (2014): 3059–3067.
- Townsend, William, and David Linch. “Hodgkin’s Lymphoma in Adults.” Lancet 380 (2012): 836–847.
- Barrington, Sally F., N. G. Mikhaeel, Lale Kostakoglu, et al. “Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group.” Journal of Clinical Oncology 32, no. 27 (2014): 3048–3058.
- Kuruvilla, J., A. Keating, and M. Crump. “How I Treat Relapsed and Refractory Hodgkin Lymphoma.” Blood 117, no. 16 (2011): 4208–4217.
- Wang, C. M., Z. Q. Wu, et al. “Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin’s Lymphoma: An Open-Label Phase 1 Trial.” Lancet 386, suppl. 12 (2015).
- Swerdlow, Steven H., Elias Campo, Nancy L. Harris, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2008.
- National Cancer Institute. Adult Hodgkin Lymphoma Treatment (PDQ®)—Health Professional Version. Bethesda, MD: National Cancer Institute. Last modified November 5, 2015. https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq
- Engert, Andreas. “Hodgkin’s Lymphoma: Who Needs Consolidation Treatment?” Lancet 385, no. 9980 (2015): 1810–1812.
